Pfizer's expenditure on research and development 2006-2020

Pfizer is a multinational pharmaceutical company that is headquartered in New York City, New York. Pfizer’s expenditures on research and development (R&D) have been variable in recent history. During 2020, Pfizer expended some 9.4 billion U.S. dollars on R&D efforts. This is a significant increase from the previous year, almost reaching the record-high from 2010 with some 9.5 billion dollars.

Pfizer’s company profile

Pfizer is one of the world’s largest pharmaceutical companies. The company has pharmaceuticals in a number of therapeutic areas including oncology, endocrinology, cardiology, and neurology. The Prevnar family of drugs is Pfizer’s top revenue-generating drug group. Prevnar is a vaccine used to prevent pneumococcal pneumonia. The company has undergone several mergers and acquisitions in recent history. In 1999 Pfizer and Warner-Lambert joined, forming one of the most valuable pharmaceutical mergers of all time.

Pharmaceutical research and development

Pharmaceutical R&D is crucial for finding and creating new drug compounds and agents that have the potential to save lives (or improve medical symptoms). Pharmaceutical R&D in the U.S. has become a booming industry and spending is increasing year-over-year. The number of federally registered clinical trials in the U.S. has been increasing significantly in recent years as well. One area of health that has been significantly impacted by R&D investment is oncology. There have never been more cancer drugs in development in the United States than in 2018.

Pfizer's expenditure on research and development from 2006 to 2020

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% discount until May 31st
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in

Release date

February 2021



Survey time period

2006 to 2020

Supplementary notes

This statistic was assembled from several editions of Pfizer's annual financial report.

Open this statistic in...
Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Pfizer"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.